Immunologic approaches to antigen discovery for cancer vaccines.
Expert Opin Investig Drugs
; 9(3): 481-90, 2000 Mar.
Article
em En
| MEDLINE
| ID: mdl-11060689
ABSTRACT
Since the early 1990s, scientists have identified an ever-expanding number of antigens to serve as targets for experimental cancer treatments, based on the stimulation of a patient's immune system. Using both immune cells and serum to screen potential candidates, several promising antigens are currently components of vaccines directed against a wide range of tumour types. These antigens vary in their tumour- and tissue-specificity. Their utility as a single reagent or as part of a multi-dimensional approach is as varied as the genes themselves. However, there are already reports indicating that the promise of evoking a clinically beneficial immune response, toward human tumours, is being fulfilled. In this review, we provide a summary of the current status of immunologic approaches to antigen discovery. We also discuss the need for additional, supportive data from non-immunologic techniques, as well as the progression of the preclinical process towards target validation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vacinas Anticâncer
/
Antígenos
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Expert Opin Investig Drugs
Assunto da revista:
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Estados Unidos